Pfizer has formed a collaboration with AbCellera Biologics, a privately held biotechnology company headquartered in Vancouver, British Columbia, Canada, to discover and develop therapeutic antibodies against undisclosed membrane protein targets using AbCellera’s proprietary monoclonal antibody screening platform.

Under the agreement, AbCellera will receive an upfront payment and research support, and will be eligible to receive up to approximately $90 million in contingent milestone payments as well as tiered mid-to-low single digit royalty payments based on Pfizer’s development and commercialization of antibodies that may be generated under this collaboration. Further terms of the agreement are not disclosed.

Source: AbCellera